Results 311 to 320 of about 257,826 (338)
Some of the next articles are maybe not open access.
Cyclophosphamide cardiotoxicity
European Journal of Pediatrics, 1980A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide (4 x 50 mg/kg on four consecutive days) given as preparation for bone marrow grafting. This and previously reported cases demonstrate the possibility of cardiotoxicity after high doses of the drug.
G, von Bernuth +6 more
openaire +2 more sources
Clinical Pharmacokinetics of Cyclophosphamide
Clinical Pharmacokinetics, 2005Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug.
Jos H. Beijnen +3 more
openaire +4 more sources
Cyclophosphamide in Pregnancy*
Australian and New Zealand Journal of Obstetrics and Gynaecology, 1970Summary: Cyclophosphamide was given to a young woman with nephrotic syndrome, and was inadvertently continued until the eighth week of her pregnancy. The baby had only two minor malformations; an umbilical hernia and a cutaneous haemangioma, which were probably not due to the cyclophosphamide.
openaire +3 more sources
CYCLOPHOSPHAMIDE THERAPY AND STERILITY
The Lancet, 1972Abstract Fourteen postpubertal male patients who had received cyclophosphamide for 16-500 days provided seminal fluid for analysis. All were azoospermic or oligospermic with or without atypical spermatozoa and reduced motility. The findings support earlier reports that cyclophosphamide therapy consistently produces testicular damage, and suggest that ...
J.H. Pennington +3 more
openaire +3 more sources
Cyclophosphamide, DCs, and Tregs
Blood, 2010Certain chemotherapeutics are now known to augment host immunity by acting on DCs. In this issue of Blood , Nakahara and colleagues demonstrate a unique pharmacologic activity of CTX to selectively eliminate the lymphoid tissue-resident CD8+ DC subset in mice.[1][1] Although chemotherapeutic ...
Akira Takashima, Hironori Matsushima
openaire +3 more sources
Synthesis of steroidal cyclophosphamides
Steroids, 1976The Reformatsky product of estrone methyl ether and ethyl bromo-acetate was transformed by two separate routes to 21-amino-3-methoxy-17alpha-pregna-1,3,5(10)-trien-17beta-ol (9). Cyclization with bis- (2-chloroethyl) phosphoramide dichloride produced the steroidal cyclophosphamide 10.
Emerson L. Foster +1 more
openaire +3 more sources
Cyclophosphamide, Cholinesterase and Anaesthesia*
Australian and New Zealand Journal of Medicine, 1972Summary: A patient receiving cyclophosphamide suffered apnoea and respiratory insufficiency after two anaesthetics in which suxamethonium had been used whilst an anaesthetic without suxamethonium was uneventful; the plasma was found to have a lowered activity of plasma cholinesterase.
P. W. Zapif, IanR. Mackay, I. R. Walker
openaire +3 more sources
The Metabolic Fate of Cyclophosphamide
Drug Metabolism Reviews, 1975(1975). The Metabolic Fate of Cyclophosphamide. Drug Metabolism Reviews: Vol. 3, No. 1, pp. 131-165.
A. R. Torkelson +2 more
openaire +3 more sources
Cyclophosphamide therapy for scleroderma
Current Opinion in Rheumatology, 1998Pulmonary manifestations are the most common cause of death in patients with scleroderma. Consequently, the importance of treatment of both interstital lung disease and pulmonary hypertension has become increasingly evident. Until a placebo-controlled study of any drug has shown its beneficial effect on pulmonary dysfunction, cyclophosphamide may be ...
openaire +3 more sources